PDCD1 and peripheral neuropathy: When PD-1/PD-L1 inhibitors plus chemotherapy were compared with chemotherapy (Figures 3B1, B2) (26–29, 50), a significant increase in the risk of peripheral neuropathy could only be seen in grades 3–5 [OR = 1.76, 95%CI:(1.10, 2.82), I2 = 0%, Z = 2.37 (P = 0.02); Figure 3B2] (26–29, 50).